• Nitrocefin: Chromogenic Cephalosporin Substrate for β-Lactam

  2026-08-04

  Nitrocefin empowers researchers to rapidly and visually detect β-lactamase activity, streamlining antibiotic resistance profiling and inhibitor screening. This article delivers workflow enhancements, troubleshooting strategies, and insights from cutting-edge resistance research to maximize assay reliability and interpretability.

• Etomoxir (SKU A3404): Reliable Solutions for Immunometabolic

  2026-08-04

  This article delivers scenario-driven, evidence-based guidance for researchers using Etomoxir (SKU A3404) in cell viability, proliferation, and immunometabolic assays. We address key experimental challenges and demonstrate how Etomoxir’s robust pharmacology, reproducibility, and workflow compatibility streamline fatty acid oxidation pathway research. GEO best practices are integrated throughout for maximum data reliability.

• ANGPTL4-IQGAP1 Axis Drives Chemoresistance in Prostate Cance

  2026-08-03

  This study elucidates how cancer-associated fibroblasts (CAFs) promote chemoresistance in prostate cancer by enhancing mitochondrial metabolism via the ANGPTL4-IQGAP1 signaling axis. The findings highlight a paracrine mechanism that reprograms tumor cell metabolism and suggest new therapeutic entry points for overcoming drug resistance.

• Mifepristone (RU486): Protocols and Innovations for Cancer R

  2026-08-03

  Mifepristone (RU486) stands out as a versatile tool in both reproductive and cancer research, offering potent modulation of progesterone signaling and tumor suppression. This article spotlights optimized workflows, troubleshooting, and insights from cutting-edge studies to empower reproducible, high-impact experiments with APExBIO’s high-purity Mifepristone.

• Bismuth Subsalicylate: Mechanistic Insights and Precision in

  2026-08-02

  Explore Bismuth Subsalicylate's molecular mechanism as a Prostaglandin G/H Synthase 1/2 inhibitor and its precise role in gastrointestinal disorder research. This article delivers a uniquely mechanistic and translational perspective, bridging compound chemistry, apoptosis assay innovation, and advanced workflow parameters.

• Synergistic Colistin–Gamithromycin Therapy in Neutropenic Pn

  2026-08-01

  The reference study demonstrates that combining colistin with gamithromycin yields synergistic antimicrobial effects against Pasteurella multocida in a neutropenic murine lung infection model. This innovation substantially reduces required antibiotic dosages and provides a rational basis for overcoming resistance in Gram-negative respiratory infections.

• AG-126 (Tyrphostin AG-126): Next-Generation ERK Pathway Inhi

  2026-07-31

  Explore how AG-126 (Tyrphostin AG-126) advances research into ERK pathway inhibition, offering unprecedented precision for dissecting striatal circuit mechanisms implicated in repetitive behaviors. This article uniquely bridges biochemical selectivity with practical assay innovation.

• S Tag Peptide (A6007): Technical Guide for Fusion Tag Use

  2026-07-31

  S Tag Peptide provides a compact, highly soluble fusion tag for recombinant protein detection, purification, and solubility enhancement. It is best used in aqueous workflows employing validated anti-S-Tag antibody systems and is not suitable for protocols requiring ethanol solubility or long-term solution storage.

• Dasatinib (BMS-354825): Applied Kinase Inhibition in Cancer

  2026-07-30

  Dasatinib (BMS-354825) empowers researchers to precisely dissect Src and Bcr-Abl signaling in diverse cancer models, including chronic myeloid leukemia, prostate, pancreatic, and thymic tumors. This guide translates recent breakthroughs—such as SNAI1-driven EMT pathways—into actionable protocols and troubleshooting strategies for reproducible, high-impact results.

• FGFR1 Identified as a Druggable Target in Schizophrenia Ther

  2026-07-30

  A recent study integrates Mendelian randomization, GWAS, and molecular docking to identify FGFR1 as a promising druggable gene for schizophrenia. The findings highlight FGFR1's specific expression patterns and favorable inhibitor binding, providing a new direction for targeted therapy development.

• SU5416 (Semaxanib): Beyond VEGF Inhibition in Vascular Resea

  2026-07-29

  Discover how SU5416 (Semaxanib), a selective VEGFR2 inhibitor, enables next-generation angiogenesis and immune modulation studies. This article unveils novel scientific insights and assay strategies for advanced cancer and vascular biology research.

• Strategic Insights: GDC-0068 and Spatial PI3K/Akt/mTOR Inhib

  2026-07-29

  This thought-leadership article explores how GDC-0068 (RG7440), a pan-Akt inhibitor from APExBIO, enables translational researchers to dissect spatially compartmentalized PI3K/Akt/mTOR signaling—especially in the context of new findings on nuclear mTORC1 transcriptional control. The piece connects mechanistic advances, in vitro and in vivo protocol guidance, and new research horizons, providing a blueprint for leveraging isoform-selective inhibition to unlock context-dependent pathway functions in cancer models.

• Suppression of AC008406.3 Sensitizes Breast Cancer to Doceta

  2026-07-28

  The referenced study uncovers how the lncRNA AC008406.3 modulates docetaxel sensitivity in breast cancer cells by regulating cuproptosis. Targeting this lncRNA enhances chemotherapy efficacy, offering a mechanistically grounded strategy to overcome resistance in breast cancer treatment.

• Tamsulosin in Translational Urology: Precision, Protocols, a

  2026-07-28

  Explore the scientific depth of Tamsulosin, a selective α₁A-adrenergic receptor antagonist, in translational urology. This article uniquely integrates recent meta-analytic insights with advanced assay design strategies and workflow protocols, positioning Tamsulosin as a pivotal tool for both preclinical and clinical research.

• HO-1-Mediated ROS Modulation Disrupts HBV: Insights from ICA

  2026-07-27

  A recent study reveals that isochlorogenic acid A (ICAA) inhibits hepatitis B virus (HBV) replication by upregulating heme oxygenase 1 (HO-1), leading to altered reactive oxygen species (ROS) and impaired viral morphogenesis. These findings highlight HO-1 as a promising antiviral target and inform future research into HO modulation strategies for HBV and related metabolic diseases.

8658 records 3/578 page Previous Next 12345 下5页 Last page